LIVE Price Database Suppliers B2B suppliers Quality & badges Encyclopedia Articles
LONGEVITY TOPICS
NAD+ Precursors Sirtuin Activators Senolytics Autophagy Mitochondrial Hormesis
About PeptideCompare Business Network Contact Policy
Home / Encyclopedia / Khavinson Bioregulators / Taxorest
MONOGRAPH No. 061
EVIDENCE BASELimited
TYPE
Natural peptide complex (cytomedin)
SEQUENCE
Proprietary complex
CAS
Not assigned
EU STATUS
Research only
WADA
Not listed
MIN PURITY
Lab-specific
Khavinson Bioregulators

Taxorest — EU research guide.

Taxorest is a Khavinson-series peptide bioregulator formulated for tracheal and bronchial epithelium, proposed to support respiratory tract cell regeneration in lung tissue aging models. It is often mentioned together with Chonluten in lung-focused research contexts.

Last reviewed:

What is Taxorest?

Taxorest is a Khavinson-series peptide bioregulator formulated for tracheal and bronchial epithelium, proposed to support respiratory tract cell regeneration in lung tissue aging models. It is often mentioned together with Chonluten in lung-focused research contexts.

What does the research show?

No PubMed-indexed study of Taxorest was found; the only human data located is an unpublished manufacturer report in chronic bronchitis. No independently replicated controlled human trials are publicly available as of mid-2026.

EU legal status

Not approved as a medicine anywhere in the EU. Available only from a small number of specialist research vendors.

⚠ As with other Khavinson respiratory bioregulators, the evidence base is narrow and concentrated in one research lineage — treat marketing claims with proportionate skepticism.
✓ Not yet tracked in PeptideCompare's price comparison. Verify any vendor's COA and sequence/identity claims directly before ordering — see our COA guide.
EVIDENCE SUMMARY
LIMITED
Chronic bronchitis in remission (unpublished manufacturer report) — A 2011 report by the institute's own medical centre describes 52 adults with chronic bronchitis in remission (31 given Taxorest plus standard therapy, 21 standard therapy only; 30 days). It reports improvement in 82% versus 57% and a higher vital capacity in the treated group (about 3654 to 4221 mL, p under 0.05). The design is given only as controlled, with no described randomisation or blinding, and it was not published in a journal.
NO HUMAN DATA
No peer-reviewed data found — No PubMed-indexed study of Taxorest in humans was found in the searches for this guide, and no animal study either, although the page mentions both. The group's 2014 review of clinical trials covers seven other preparations. Independent replication is absent.

Molecular information

CAS number
Not assigned

Pharmacokinetics

No established human pharmacokinetic data. Published human PK parameters for this compound are not available; reported data are limited to animal models or absent. No curve is shown, to avoid implying data that does not exist.

Potency retained over time

Each line is one storage condition: it starts at 100% and falls as potency is lost. Above the dashed 80% line the material is considered reliable — hover for exact values.

Freezer −20 °C
36+ mo
Stable · >95% potency
Fridge 4 °C
3-4 mo
In use · after recon
Room 20 °C
10-13 days
Limited · moderate loss
Warm 37 °C+
2-3 days
Critical · rapid degradation

⚠ Modelled per compound from molecular structure — chain length, cyclisation, oxidation- and deamidation-prone residues and light sensitivity. Indicative only, not lab-measured per batch.

Taxorest is not yet in our price comparison

We expand EU supplier coverage every month.

References

  1. Unpublished manufacturer report posted by a vendor (52 participants, 2011). It is included for transparency only: no peer review, no full methods, and it is not independent evidence. Saint Petersburg Institute of Bioregulation and Gerontology Medical Center. Report of clinical study of the peptide bioregulator Taxorest, April-November 2011 (unpublished manufacturer report as posted by a vendor; no journal citation). Source
  2. Group review of clinical trials of seven peptide bioregulators. Taxorest is not among them, so it gives no human evidence for this compound; it is also written by the developers. Khavinson VKh, Kuznik BI, Ryzhak GA. Peptide bioregulators: a new class of geroprotectors. Report 2: The results of clinical trials. Adv Gerontol. 2014;4(4):346-361. DOI
  3. Group review of animal studies of peptide bioregulators. It lists bronchial-mucosa preparations only among many tissues, gives no product-specific data for Taxorest, and all data come from the originating group. Khavinson VKh, Kuznik BI, Ryzhak GA. Peptide bioregulators: a new class of geroprotectors. Message 1: Results of experimental studies. Adv Gerontol. 2013;3(3):225-235. DOI

Related guides

Khavinson Bioregulators

Bolamin
Khavinson Bioregulators

Bronchogen
Khavinson Bioregulators

Cardiogen
PeptideCompare AssistantOnline · replies instantly
Hi! I help you quickly find the right page — about legality, COAs, badges or suppliers. No price advice, no dosing.
Try a question
Find a supplier Questions about a peptide? Read our articles Compare prices Is this legal in the EU? How to read a COA What do badges mean? Will customs stop my order? What is BAC water? Talk to a doctor first?
Navigation assistant · no medical advice